Purpose of the study
====================

To investigate the potential of a commonly used botanical supplement, Echinacea purpurea, to interact with the boosted protease inhibitor darunavir/ritonavir.

Methods
=======

Open-label, fixed-sequence study in 15 HIV-infected patients receiving antiretroviral therapy including darunavir/ritonavir (600/100 mg twice daily) for at least 4 weeks. Echinacea purpurea root extract-containing capsules were added to the antiretroviral treatment (500 mg every 6 hours) from days 1 to 14. Darunavir concentrations in plasma were determined by using HPLC immediately before and 1, 2, 4, 6, 8, 10 and 12 hours after a morning dose of darunavir/ritonavir on days 0 (darunavir/ritonavir) and 14 (darunavir/ritonavir + echinacea). Individual darunavir pharmacokinetic parameters were calculated by using non-compartmental analysis, and were compared between days 0 and 14 by using the geometric mean ratio (GMR) and its 95% confidence interval (95% CI).

Results
=======

Median (range) age was 49 (43-67) years, and body mass index was 24.2 (18.7-27.5) kg/m^2^. Echinacea was well tolerated and all participants completed the study. Relative to administration of darunavir/ritonavir alone, its coadministration with Echinacea purpurea resulted in little change in darunavir pharmacokinetic parameters. Table [1](#T1){ref-type="table"}

                   DRV/r              DRV/r + Echinacea   GMR (95% CI)       p
  ---------------- ------------------ ------------------- ------------------ -------
  Cτ (ng/mL)       2.1 (1.6-2.7)      1.7 (1.4-2.2)       0.84 (0.59-1.19)   0.311
                                                                             
  AUCτ (ng.h/mL)   46.2 (39.0-54.7)   41.6 (35.1-49.2)    0.90 (0.71-1.14)   0.374
                                                                             
  Cmax (ng/mL)     6.4 (5.5-7.4)      6.2 (5.3-7.25)      0.98 (0.79-1.21)   0.810

Conclusions
===========

coadministration of Echinacea purpurea with darunavir/ritonavir was safe and well tolerated in HIV-infected patients; data suggest that no dose adjustment for darunavir/ritonavir is necessary.
